<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:hpo ids='HP_0005575'>Hemolytic uremic syndrome</z:hpo> (HUS) has been reported in patients treated with <z:chebi fb="0" ids="4031">cyclosporin A</z:chebi> (CsA) following bone, hepatic and kidney transplantation </plain></SENT>
<SENT sid="1" pm="."><plain>We report two patients with <z:chebi fb="6" ids="22696">Beh</z:chebi>Ã§et's disease (BD) under CsA treatment because of severe <z:hpo ids='HP_0000554'>uveitis</z:hpo>, who developed HUS several months after the initiation of treatment </plain></SENT>
<SENT sid="2" pm="."><plain>Renal biopsies showed lesions consistent with the diagnosis of the arterial form of <z:e sem="disease" ids="C0034155" disease_type="Disease or Syndrome" abbrv="">thrombotic microangiopathy</z:e>: vascular <z:mp ids='MP_0005048'>thrombosis</z:mp> with extensive glomerular <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain><z:hpo ids='HP_0000083'>Renal failure</z:hpo> persisted after withdrawal of CsA: one patient is in <z:hpo ids='HP_0003774'>chronic renal failure</z:hpo> (CRF) with a 4-year follow-up; the other died after refusal of <z:hpo ids='HP_0011010'>chronic</z:hpo> hemodialysis </plain></SENT>
<SENT sid="4" pm="."><plain>In our two patients, excessive doses of CsA with high trough levels are likely to have contributed to the development of HUS </plain></SENT>
<SENT sid="5" pm="."><plain>A rapid adjustment of CsA doses and an early detection of signs of the microangiopathic process might have prevented this severe complication of CsA treatment </plain></SENT>
</text></document>